654:
InChI=1S/C230H324N67O122P19S19/c1-97-55-278(217(309)256-177(97)231)141-45-111(122(381-141)70-362-422(325,441)404-116-50-146(283-66-108(12)196(302)275-228(283)320)387-128(116)76-368-427(330,446)410-120-54-150(294-93-253-154-191(294)266-214(243)270-200(154)306)390-130(120)78-370-428(331,447)408-118-52-148(292-91-250-151-186(240)246-89-248-188(151)292)388-131(118)79-371-430(333,449)412-159-134(394-204(169(159)354-37-27-344-17)286-59-101(5)181(235)260-221(286)313)83-375-435(338,454)417-164-138(398-209(174(164)359-42-32-349-22)291-68-110(14)198(304)277-230(291)322)87-377-434(337,453)415-162-136(396-207(172(162)357-40-30-347-20)289-62-104(8)184(238)263-224(289)316)85-376-433(336,452)414-161-133(393-206(171(161)356-39-29-346-19)288-61-103(7)183(237)262-223(288)315)82-374-432(335,451)411-158-121(69-298)391-211(168(158)353-36-26-343-16)296-95-254-155-192(296)267-215(244)271-201(155)307)401-420(323,439)365-74-127-117(51-147(386-127)284-67-109(13)197(303)276-229(284)321)406-425(328,444)369-77-129-119(53-149(389-129)293-92-252-153-190(293)265-213(242)269-199(153)305)409-426(329,445)367-71-123-112(46-142(382-123)279-56-98(2)178(232)257-218(279)310)402-421(324,440)364-73-125-115(49-145(384-125)282-65-107(11)195(301)274-227(282)319)405-424(327,443)366-75-126-114(48-144(385-126)281-64-106(10)194(300)273-226(281)318)403-423(326,442)363-72-124-113(47-143(383-124)280-57-99(3)179(233)258-219(280)311)407-429(332,448)373-81-139-166(176(361-44-34-351-24)212(400-139)297-96-255-156-193(297)268-216(245)272-202(156)308)419-438(341,457)379-86-137-163(173(358-41-31-348-21)208(397-137)290-63-105(9)185(239)264-225(290)317)416-436(339,455)380-88-140-165(175(360-43-33-350-23)210(399-140)295-94-251-152-187(241)247-90-249-189(152)295)418-437(340,456)378-84-135-160(170(355-38-28-345-18)205(395-135)287-60-102(6)182(236)261-222(287)314)413-431(334,450)372-80-132-157(299)167(352-35-25-342-15)203(392-132)285-58-100(4)180(234)259-220(285)312/h55-68,89-96,111-150,157-176,203-212,298-299H,25-54,69-88H2,1-24H3,(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H,341,457)(H2,231,256,309)(H2,232,257,310)(H2,233,258,311)(H2,234,259,312)(H2,235,260,313)(H2,236,261,314)(H2,237,262,315)(H2,238,263,316)(H2,239,264,317)(H2,240,246,248)(H2,241,247,249)(H,273,300,318)(H,274,301,319)(H,275,302,320)(H,276,303,321)(H,277,304,322)(H3,242,265,269,305)(H3,243,266,270,306)(H3,244,267,271,307)(H3,245,268,272,308)/t111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,203+,204+,205+,206+,207+,208+,209+,210+,211+,212+,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?/m0/s1
634:
COCCO1(OP(=S)(OC2O(C2OP(=S)(OC2O(C2OP(=S)(OC2O(C2OP(=S)(OC2O(C2OP(=S)(OC2O(C2OP(=S)(OC2O(C2OP(=S)(OC2O(C2OP(=S)(OC2O(C2OP(=S)(OC2O(C2OP(=S)(OC2O(C2OP(=S)(OC2O((2OP(=S)(OC2O((2OP(=S)(OC2O((2OP(=S)(OC2O((2OP(=S)(OC2O((2O)OCCOC)n2cc(C)c(nc2=O)N)O)OCCOC)n2cc(C)c(nc2=O)N)O)OCCOC)n2cnc3c2ncnc3N)O)OCCOC)n2cc(C)c(nc2=O)N)O)OCCOC)n2cnc3c2nc(N)c3=O)O)n2cc(C)c(nc2=O)N)O)n2cc(C)c(=O)c2=O)O)n2cc(C)c(=O)c2=O)O)n2cc(C)c(nc2=O)N)O)n2cnc3c2nc(N)c3=O)O)n2cc(C)c(=O)c2=O)O)n2cc(C)c(nc2=O)N)O)n2cc(C)c(=O)c2=O)O)n2cnc3c2nc(N)c3=O)O)n2cnc3c2ncnc3N)O)(O1n1cc(C)c(nc1=O)N)COP(=S)(O1(COP(=S)(O2(COP(=S)(O3(COP(=S)(O4(CO)O(4OCCOC)n4cnc5c4nc(N)c5=O)O)O(3OCCOC)n3cc(C)c(nc3=O)N)O)O(2OCCOC)n2cc(C)c(nc2=O)N)O)O(1OCCOC)n1cc(C)c(=O)c1=O)O
522:
29:
857:
849:
759:
In clinical trials, 18% of subjects taking mipomersen stopped using the drug due to adverse effects; the most common adverse effects leading to discontinuation were injection site reactions, increases of transaminases, flu-like symptoms (fever, chills, abdominal pain, nausea, vomiting), and abnormal
719:
Mipomersen is pregnancy category B; women who are pregnant or intending to become pregnant should only use this drug if needed. It is unknown if it is secreted in human breast milk, but it was found to be secreted in the breast milk of rats.
1158:"Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B"
1089:
Feingold KR, Grunfeld C (August 10, 2016). "Cholesterol
Lowering Drugs". In Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. (eds.).
1205:
1245:
1705:
961:
949:
937:
91:
1332:
1024:
in 2008 by an auction bid. Ionis earned an upfront payment of $ 325 million, with payments of a further $ 825 million if milestones are met.
59:
626:
1227:
832:, which is convenient since apolipoprotein B predominantly acts there. Protein binding is over 90%. The molecule is slowly broken up by
728:
The drug is contraindicated in people with moderate to severe liver impairment, active liver diseases, and unexplained high levels of
1999:
708:
1584:
1263:
1140:"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 61"
2053:
2107:
1325:
840:. After 24 hours, less than 4% of the degradation products are found in the urine, and overall half-life is 1 to 2 months.
1213:
673:
646:
2070:
1363:
1318:
207:
121:
828:
After subcutaneous injection, mipomersen reaches highest blood levels after 3 to 4 hours. It accumulates in the
1139:
2102:
1035:
892:-methoxyethyl-modified ribose at the two ends. These modifications make the drug resistant to degradation by
701:
681:
1588:
1354:
1288:
809:
433:
1073:"Kynamro (mipomersen sodium) Injection, Solution for Subcutaneous Injection. Full Prescribing Information"
1034:
In
January 2013, The United States Food and Drug Administration approved mipomersen for the treatment of
501:
490:
1072:
2014:
1028:
865:
517:
1913:
1879:
1794:
1536:
2058:
1938:
1933:
1908:
1875:
1837:
1621:
1540:
1476:
1403:
805:
77:
41:
779:
Other drugs known for causing liver problems might add to mipomersen's risk of liver damage. No
2097:
1923:
1918:
685:
154:
84:
1031:
in 2012 and again in 2013 due to concerns about the liver and cardiovascular adverse effects.
422:
1928:
1395:
1017:
881:
817:
349:
357:
1969:
1695:
1554:
801:
450:
442:
176:
521:
8:
1341:
1021:
340:
707:
It cannot be freely prescribed; instead every person put on mipomersen is enrolled in a
1953:
1399:
1182:
1157:
692:
from this drug and it can only be prescribed in the context of a risk management plan.
1948:
1617:
1574:
1472:
1187:
1096:
753:
741:
382:
136:
1177:
1169:
981:
977:
969:
921:
913:
909:
877:
538:
146:
104:
2112:
1833:
1649:
917:
780:
164:
1090:
2064:
1790:
1630:
945:
929:
925:
873:
813:
1310:
1289:"FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder"
1173:
2091:
1437:
1427:
869:
797:
1125:
69:
28:
2039:
1715:
1710:
1677:
1668:
1640:
1569:
1520:
1510:
1490:
1485:
1345:
1191:
1100:
833:
749:
745:
729:
689:
99:
20:
2019:
1994:
1974:
1943:
1851:
1823:
1818:
1813:
1808:
1803:
1755:
1750:
1740:
1735:
1700:
1607:
1597:
1525:
1515:
1495:
1445:
1412:
885:
837:
402:
2034:
1989:
1984:
1979:
1888:
1861:
1856:
1846:
1760:
1730:
1725:
1720:
1654:
1602:
1564:
1505:
1500:
1422:
1417:
1380:
589:
413:
1745:
1432:
1385:
1375:
1120:
973:
965:
957:
953:
941:
933:
905:
893:
368:
189:
63:
856:
2029:
2024:
2004:
1776:
1549:
1441:
470:
393:
169:
1871:
1687:
1246:"Refusal of the marketing authorisation for Kynamro (mipomersen)"
1228:"EMA committee shoots down Sanofi's cholesterol drug mipomersen"
1559:
1468:
1367:
764:
481:
771:, pain in legs or arms, headache, insomnia, and hypertension.
1459:
848:
829:
768:
607:
812:(VLDL). As a consequence, the RNA is degraded by the enzyme
506:
461:
763:
Other adverse effects include: heart problems including
748:; specifically it can cause elevations in the levels of
331:-(2-methoxyethyl)-5-methylcytidine nonadecasodiumsalt
1264:"F.D.A. Approves Genetic Drug to Treat Rare Disease"
1016:
The drug was discovered and developed to Phase 2 by
804:(ApoB-100), a protein that is the main component of
1206:"Genzyme and Isis Complete Licensing of Mipomersen"
1251:. European Medicines Agency (EMA). March 21, 2013.
2089:
1155:
1088:
381:
1340:
1156:Geary RS, Baker BF, Crooke ST (February 2015).
356:
348:
16:Drug used to treat genetic hypercholesterolemia
1326:
1116:
1114:
1112:
1110:
267:- thiothymidylyl-(3’→5’)-2’-deoxy-5-methyl-
1333:
1319:
899:The complete sequence is portrayed below:
888:in the middle part of the molecule and 2’-
714:
520:
421:
291:-thiothymidylyl-(3’→5’)-2’-deoxy-5-methyl-
2000:Magnesium pyridoxal 5-phosphate glutamate
1181:
1095:. South Dartmouth (MA): MDText.com, Inc.
896:, allowing it to be administered weekly.
709:Risk Evaluation and Mitigation Strategies
449:
441:
1107:
1036:homozygous familial hypercholesterolemia
855:
847:
279:-thioguanylyl-(3’→5’)-2’-deoxy-5-methyl-
1261:
516:
401:
2090:
864:The compound is a 'second-generation'
791:
1314:
1124:
680:) is a drug used to treat homozygous
489:
130:
68:
1149:
1067:
1065:
1063:
1061:
1059:
1057:
1055:
1053:
1051:
723:
711:(REMS) program approved by the FDA.
700:Kynamro is used to treat homozygous
103:
1078:. Kastle Therapeutics, Chicago, IL.
823:
469:
372:
13:
1145:. World Health Organization. 2009.
868:; the nucleotides are linked with
783:interactions have been described.
735:
704:and is administered by injection.
573:
14:
2124:
1364:Cholesterol absorption inhibitors
1293:U.S. Food and Drug Administration
1048:
275:-thiothymidylyl-(3’→5’)-2’-deoxy-
555:
549:
255:-thiocytidylyl-(3’→5’)-2’-deoxy-
194:<4% in urine in 24 hours
27:
1281:
1027:Mipomersen was rejected by the
786:
774:
659:Key:XLTMQWVJFPYGMC-QVKFEXRMSA-N
259:-thioadenylyl-(3’→5’)-2’-deoxy-
1255:
1238:
1220:
1212:. 24 June 2008. Archived from
1198:
1132:
1082:
695:
688:. There is a serious risk of
579:
567:
561:
543:
1:
1262:Pollack A (29 January 2013).
1041:
1020:and subsequently licensed to
702:familial hypercholesterolemia
682:familial hypercholesterolemia
843:
810:very low-density lipoprotein
7:
2108:Therapeutic gene modulation
1092:Endotext [Internet]
323:-(2-methoxyethyl)-5-methyl-
307:-(2-methoxyethyl)-5-methyl-
251:-(2-methoxyethyl)-5-methyl-
243:-(2-methoxyethyl)-5-methyl-
235:-(2-methoxyethyl)-5-methyl-
227:-(2-methoxyethyl)-5-methyl-
70:Multum Consumer Information
10:
2129:
1011:
884:, and the sugar parts are
533:Chemical and physical data
327:-thiocytidylyl-(3’→5’)-2’-
319:-thioadenylyl- (3’→5’)-2’-
311:-thiocytidylyl-(3’→5’)-2’-
295:-thiocytidylyl-(3’→5’)-2’-
239:-thiocytidylyl-(3’→5’)-2’-
231:-thiocytidylyl-(3’→5’)-2’-
2048:
2015:Omega−3-acid ethyl esters
1962:
1901:
1870:
1832:
1789:
1769:
1686:
1676:
1667:
1639:
1616:
1583:
1534:
1467:
1458:
1394:
1362:
1353:
1174:10.1007/s40262-014-0224-4
1162:Clinical Pharmacokinetics
1029:European Medicines Agency
872:linkages rather than the
866:antisense oligonucleotide
860:Complete skeletal formula
642:
622:
605:
588:
537:
532:
500:
480:
460:
432:
412:
392:
367:
339:
303:-thioguanylyl-(3’→5’)-2’-
247:-thiouridylyl-(3’→5’)-2’-
223:-thioguanylyl-(3’→5’)-2’-
203:
198:
188:
175:
163:
153:
145:
120:
115:
90:
76:
58:
50:
40:
35:
26:
1914:Bempedoic acid/ezetimibe
1535:Niacin and derivatives (
796:Mipomersen binds to the
287:-thiothymidylyl-(3’→5’)-
1939:Fenofibrate/simvastatin
1934:Fenofibrate/pravastatin
1909:Amlodipine/atorvastatin
1126:Professional Drug Facts
806:low-density lipoprotein
715:Pregnancy and lactation
684:and is administered by
283:-thiocytidylyl-(3’→5’)-
271:-thiocytidylyl-(3’→5’)-
1924:Ezetimibe/rosuvastatin
1919:Ezetimibe/atorvastatin
1396:Bile acid sequestrants
861:
853:
816:, and ApoB-100 is not
686:subcutaneous injection
263:-thioguanylyl-(3’→5’)-
85:Subcutaneous injection
1929:Ezetimibe/simvastatin
1342:Lipid-lowering agents
1216:on 29 September 2011.
1018:Ionis Pharmaceuticals
859:
851:
2103:Hypolipidemic agents
1970:Alipogene tiparvovec
1696:Aluminium clofibrate
1555:Aluminium nicotinate
1234:. December 14, 2012.
836:and subsequently by
802:apolipoprotein B-100
1706:Choline fenofibrate
1022:Genzyme Corporation
792:Mechanism of action
754:fatty liver disease
23:
2075:Never to phase III
1954:Niacin/simvastatin
1944:Niacin/laropiprant
1268:The New York Times
862:
854:
852:Chemical structure
767:and palpitations,
744:about the risk of
448:sodium salt:
355:sodium salt:
315:-(2-methoxyethyl)-
299:-(2-methoxyethyl)-
219:-(2-Methoxyethyl)-
19:
2085:
2084:
1949:Niacin/lovastatin
1897:
1896:
1785:
1784:
1663:
1662:
1618:ATP citrate lyase
1575:Nicotinyl alcohol
1473:HMG-CoA reductase
1454:
1453:
1295:. 29 January 2013
995:-(2-methoxyethyl)
742:black box warning
724:Contraindications
667:
666:
502:CompTox Dashboard
134:
2120:
1834:PCSK9 inhibitors
1684:
1683:
1674:
1673:
1465:
1464:
1360:
1359:
1335:
1328:
1321:
1312:
1311:
1305:
1304:
1302:
1300:
1285:
1279:
1278:
1276:
1274:
1259:
1253:
1252:
1250:
1242:
1236:
1235:
1224:
1218:
1217:
1202:
1196:
1195:
1185:
1153:
1147:
1146:
1144:
1136:
1130:
1128:
1118:
1105:
1104:
1086:
1080:
1079:
1077:
1069:
1006:
1000:
990:
985:
870:phosphorothioate
824:Pharmacokinetics
600:
598:
581:
575:
569:
563:
557:
551:
545:
525:
524:
510:
508:
493:
473:
453:
445:
425:
405:
385:
375:
374:
360:
352:
180:
132:
129:
107:
72:
31:
24:
22:
18:
2128:
2127:
2123:
2122:
2121:
2119:
2118:
2117:
2088:
2087:
2086:
2081:
2080:
2065:Clinical trials
2044:
1958:
1893:
1866:
1828:
1791:CETP inhibitors
1781:
1765:
1659:
1650:Dextrothyroxine
1635:
1612:
1579:
1530:
1450:
1390:
1349:
1339:
1309:
1308:
1298:
1296:
1287:
1286:
1282:
1272:
1270:
1260:
1256:
1248:
1244:
1243:
1239:
1226:
1225:
1221:
1204:
1203:
1199:
1154:
1150:
1142:
1138:
1137:
1133:
1119:
1108:
1087:
1083:
1075:
1071:
1070:
1049:
1044:
1014:
1004:
998:
988:
903:
846:
826:
794:
789:
781:pharmacokinetic
777:
740:The drug has a
738:
736:Adverse effects
732:liver enzymes.
726:
717:
698:
663:
660:
655:
650:
649:
638:
635:
630:
629:
618:
596:
594:
584:
578:
572:
566:
560:
554:
548:
528:
504:
496:
476:
456:
428:
408:
388:
371:
363:
335:
332:
211:
210:
178:
155:Protein binding
147:Pharmacokinetic
141:
111:
79:
17:
12:
11:
5:
2126:
2116:
2115:
2110:
2105:
2100:
2083:
2082:
2079:
2078:
2077:
2076:
2073:
2062:
2056:
2050:
2049:
2046:
2045:
2043:
2042:
2037:
2032:
2027:
2022:
2017:
2012:
2007:
2002:
1997:
1992:
1987:
1982:
1977:
1972:
1966:
1964:
1960:
1959:
1957:
1956:
1951:
1946:
1941:
1936:
1931:
1926:
1921:
1916:
1911:
1905:
1903:
1899:
1898:
1895:
1894:
1892:
1891:
1885:
1883:
1868:
1867:
1865:
1864:
1859:
1854:
1849:
1843:
1841:
1830:
1829:
1827:
1826:
1821:
1816:
1811:
1806:
1800:
1798:
1787:
1786:
1783:
1782:
1780:
1779:
1773:
1771:
1767:
1766:
1764:
1763:
1758:
1753:
1748:
1743:
1738:
1733:
1728:
1723:
1718:
1713:
1708:
1703:
1698:
1692:
1690:
1681:
1671:
1665:
1664:
1661:
1660:
1658:
1657:
1652:
1646:
1644:
1637:
1636:
1634:
1633:
1631:Bempedoic acid
1627:
1625:
1614:
1613:
1611:
1610:
1605:
1600:
1594:
1592:
1581:
1580:
1578:
1577:
1572:
1567:
1562:
1557:
1552:
1546:
1544:
1532:
1531:
1529:
1528:
1523:
1518:
1513:
1508:
1503:
1498:
1493:
1488:
1482:
1480:
1462:
1456:
1455:
1452:
1451:
1449:
1448:
1435:
1430:
1425:
1420:
1415:
1409:
1407:
1392:
1391:
1389:
1388:
1383:
1378:
1372:
1370:
1357:
1351:
1350:
1338:
1337:
1330:
1323:
1315:
1307:
1306:
1280:
1254:
1237:
1219:
1197:
1168:(2): 133–146.
1148:
1131:
1106:
1081:
1046:
1045:
1043:
1040:
1013:
1010:
1009:
1008:
1002:
996:
986:
874:phosphodiester
845:
842:
825:
822:
814:ribonuclease H
793:
790:
788:
785:
776:
773:
737:
734:
725:
722:
716:
713:
697:
694:
665:
664:
662:
661:
658:
656:
653:
645:
644:
643:
640:
639:
637:
636:
633:
625:
624:
623:
620:
619:
617:
616:
613:
611:
603:
602:
592:
586:
585:
582:
576:
570:
564:
558:
552:
546:
541:
535:
534:
530:
529:
527:
526:
518:DTXSID20212108
513:
511:
498:
497:
495:
494:
486:
484:
478:
477:
475:
474:
466:
464:
458:
457:
455:
454:
446:
438:
436:
430:
429:
427:
426:
418:
416:
410:
409:
407:
406:
398:
396:
390:
389:
387:
386:
378:
376:
365:
364:
362:
361:
353:
345:
343:
337:
336:
334:
333:
214:
206:
205:
204:
201:
200:
196:
195:
192:
186:
185:
182:
173:
172:
167:
161:
160:
157:
151:
150:
143:
142:
140:
139:
126:
124:
118:
117:
113:
112:
110:
109:
96:
94:
88:
87:
82:
80:administration
74:
73:
66:
56:
55:
52:
48:
47:
44:
38:
37:
33:
32:
15:
9:
6:
4:
3:
2:
2125:
2114:
2111:
2109:
2106:
2104:
2101:
2099:
2098:Antisense RNA
2096:
2095:
2093:
2074:
2072:
2069:
2068:
2066:
2063:
2060:
2057:
2055:
2052:
2051:
2047:
2041:
2038:
2036:
2033:
2031:
2028:
2026:
2023:
2021:
2018:
2016:
2013:
2011:
2008:
2006:
2003:
2001:
1998:
1996:
1993:
1991:
1988:
1986:
1983:
1981:
1978:
1976:
1973:
1971:
1968:
1967:
1965:
1961:
1955:
1952:
1950:
1947:
1945:
1942:
1940:
1937:
1935:
1932:
1930:
1927:
1925:
1922:
1920:
1917:
1915:
1912:
1910:
1907:
1906:
1904:
1900:
1890:
1887:
1886:
1884:
1881:
1877:
1873:
1869:
1863:
1860:
1858:
1855:
1853:
1850:
1848:
1845:
1844:
1842:
1839:
1835:
1831:
1825:
1822:
1820:
1817:
1815:
1812:
1810:
1807:
1805:
1802:
1801:
1799:
1796:
1792:
1788:
1778:
1775:
1774:
1772:
1768:
1762:
1759:
1757:
1754:
1752:
1749:
1747:
1744:
1742:
1739:
1737:
1734:
1732:
1729:
1727:
1724:
1722:
1719:
1717:
1714:
1712:
1709:
1707:
1704:
1702:
1699:
1697:
1694:
1693:
1691:
1689:
1685:
1682:
1679:
1678:PPAR agonists
1675:
1672:
1670:
1669:Blood vessels
1666:
1656:
1653:
1651:
1648:
1647:
1645:
1642:
1641:Thyromimetics
1638:
1632:
1629:
1628:
1626:
1623:
1619:
1615:
1609:
1606:
1604:
1601:
1599:
1596:
1595:
1593:
1590:
1586:
1582:
1576:
1573:
1571:
1568:
1566:
1563:
1561:
1558:
1556:
1553:
1551:
1548:
1547:
1545:
1542:
1538:
1533:
1527:
1524:
1522:
1519:
1517:
1514:
1512:
1509:
1507:
1504:
1502:
1499:
1497:
1494:
1492:
1489:
1487:
1484:
1483:
1481:
1478:
1474:
1470:
1466:
1463:
1461:
1457:
1447:
1443:
1439:
1438:Soluble fiber
1436:
1434:
1431:
1429:
1428:Colestyramine
1426:
1424:
1421:
1419:
1416:
1414:
1411:
1410:
1408:
1405:
1401:
1397:
1393:
1387:
1384:
1382:
1379:
1377:
1374:
1373:
1371:
1369:
1365:
1361:
1358:
1356:
1352:
1347:
1343:
1336:
1331:
1329:
1324:
1322:
1317:
1316:
1313:
1294:
1290:
1284:
1269:
1265:
1258:
1247:
1241:
1233:
1232:FierceBiotech
1229:
1223:
1215:
1211:
1210:FreshNews.com
1207:
1201:
1193:
1189:
1184:
1179:
1175:
1171:
1167:
1163:
1159:
1152:
1141:
1135:
1127:
1123:: Mipomersen
1122:
1117:
1115:
1113:
1111:
1102:
1098:
1094:
1093:
1085:
1074:
1068:
1066:
1064:
1062:
1060:
1058:
1056:
1054:
1052:
1047:
1039:
1037:
1032:
1030:
1025:
1023:
1019:
1003:
997:
994:
987:
983:
979:
975:
971:
967:
963:
959:
955:
951:
947:
943:
939:
935:
931:
927:
923:
919:
915:
911:
907:
902:
901:
900:
897:
895:
891:
887:
883:
879:
875:
871:
867:
858:
850:
841:
839:
835:
834:endonucleases
831:
821:
819:
815:
811:
807:
803:
799:
798:messenger RNA
784:
782:
772:
770:
766:
761:
760:liver tests.
757:
755:
751:
750:transaminases
747:
743:
733:
731:
721:
712:
710:
705:
703:
693:
691:
687:
683:
679:
676:; trade name
675:
671:
657:
652:
651:
648:
641:
632:
631:
628:
621:
615:
614:
612:
609:
604:
593:
591:
587:
542:
540:
536:
531:
523:
519:
515:
514:
512:
503:
499:
492:
488:
487:
485:
483:
479:
472:
468:
467:
465:
463:
459:
452:
447:
444:
440:
439:
437:
435:
431:
424:
420:
419:
417:
415:
411:
404:
400:
399:
397:
395:
391:
384:
380:
379:
377:
370:
366:
359:
354:
351:
347:
346:
344:
342:
338:
330:
326:
322:
318:
314:
310:
306:
302:
298:
294:
290:
286:
282:
278:
274:
270:
266:
262:
258:
254:
250:
246:
242:
238:
234:
230:
226:
222:
218:
213:
212:
209:
202:
197:
193:
191:
187:
183:
181:
174:
171:
168:
166:
162:
158:
156:
152:
148:
144:
138:
128:
127:
125:
123:
119:
114:
106:
101:
98:
97:
95:
93:
89:
86:
83:
81:
75:
71:
67:
65:
61:
57:
53:
49:
45:
43:
39:
36:Clinical data
34:
30:
25:
2040:Volanesorsen
2009:
1902:Combinations
1874:inhibitors (
1716:Clinofibrate
1711:Ciprofibrate
1620:inhibitors (
1587:inhibitors (
1570:Nicofuranose
1521:Rosuvastatin
1511:Pitavastatin
1491:Cerivastatin
1486:Atorvastatin
1297:. Retrieved
1292:
1283:
1271:. Retrieved
1267:
1257:
1240:
1231:
1222:
1214:the original
1209:
1200:
1165:
1161:
1151:
1134:
1091:
1084:
1033:
1026:
1015:
992:
898:
889:
876:linkages of
863:
838:exonucleases
827:
795:
787:Pharmacology
778:
775:Interactions
762:
758:
746:liver damage
739:
730:transaminase
727:
718:
706:
699:
690:liver damage
677:
669:
668:
491:ChEMBL502097
350:1000120-98-8
328:
324:
320:
316:
312:
308:
304:
300:
296:
292:
288:
284:
280:
276:
272:
268:
264:
260:
256:
252:
248:
244:
240:
236:
232:
228:
224:
220:
216:
177:Elimination
122:Legal status
116:Legal status
2061:from market
2020:Policosanol
1995:Lapaquistat
1975:Azacosterol
1852:Bococizumab
1824:Torcetrapib
1819:Obicetrapib
1814:Evacetrapib
1809:Dalcetrapib
1804:Anacetrapib
1756:Ronifibrate
1751:Pemafibrate
1741:Gemfibrozil
1736:Fenofibrate
1701:Bezafibrate
1608:Mitratapide
1598:Dirlotapide
1526:Simvastatin
1516:Pravastatin
1496:Fluvastatin
1446:glucomannan
1413:Colesevelam
886:deoxyribose
800:coding for
752:and causes
696:Indications
601: g·mol
358:629167-92-6
199:Identifiers
54:ISIS 301012
51:Other names
42:Trade names
2092:Categories
2035:Triparanol
2010:Mipomersen
1990:Darapladib
1985:Benfluorex
1980:Azalanstat
1889:Evinacumab
1862:Inclisiran
1857:Evolocumab
1847:Alirocumab
1761:Simfibrate
1731:Etofibrate
1726:Clofibride
1721:Clofibrate
1655:Resmetirom
1603:Lomitapide
1565:Niceritrol
1506:Mevastatin
1501:Lovastatin
1423:Colestipol
1418:Colestilan
1381:Hyzetimibe
1299:31 January
1273:31 January
1042:References
1007:= 2’-deoxy
1001:= 5-methyl
818:translated
808:(LDL) and
670:Mipomersen
606:3D model (
590:Molar mass
451:18EAY4870E
443:9GJ8S4GU0M
414:ChemSpider
341:CAS Number
208:IUPAC name
184:1–2 months
165:Metabolism
21:Mipomersen
2071:Phase III
2059:Withdrawn
1746:Nafenopin
1433:Colextran
1386:SCH-48461
1376:Ezetimibe
1121:Drugs.com
894:nucleases
844:Chemistry
190:Excretion
179:half-life
170:Nucleases
78:Routes of
64:Drugs.com
2030:Tiadenol
2025:Probucol
2005:Meglutol
1777:GW501516
1688:Fibrates
1550:Acipimox
1442:psyllium
1440:such as
1355:GI tract
1192:25559341
1101:27809434
423:24710309
394:DrugBank
383:44564107
92:ATC code
1872:ANGPTL3
1469:Statins
1183:4305106
1012:History
678:Kynamro
539:Formula
403:DB05528
369:PubChem
108:)
102: (
100:C10AX11
46:Kynamro
2113:Sanofi
2054:WHO-EM
1770:Others
1643:(VLDL)
1560:Niacin
1400:resins
1368:NPC1L1
1190:
1180:
1099:
765:angina
627:SMILES
482:ChEMBL
471:D08946
137:℞-only
135:
1963:Other
1680:(LDL)
1460:Liver
1249:(PDF)
1143:(PDF)
1076:(PDF)
991:= 2’-
830:liver
769:edema
647:InChI
608:JSmol
1589:VLDL
1585:MTTP
1539:and
1444:and
1301:2013
1275:2013
1188:PMID
1097:PMID
984:*—3’
880:and
462:KEGG
434:UNII
159:≥90%
149:data
60:AHFS
1880:HDL
1876:LDL
1838:LDL
1795:HDL
1622:LDL
1541:LDL
1537:HDL
1477:LDL
1404:LDL
1346:C10
1178:PMC
1170:doi
962:dmC
950:dmC
938:dmC
904:5’—
882:DNA
878:RNA
674:INN
599:.76
597:594
571:122
553:305
547:230
507:EPA
373:CID
215:2’-
105:WHO
2094::
2067::
1475:,
1366:,
1291:.
1266:.
1230:.
1208:.
1186:.
1176:.
1166:54
1164:.
1160:.
1109:^
1050:^
1038:.
982:mC
980:*—
978:mC
976:*—
972:*—
970:mC
968:*—
958:dT
954:dT
946:dG
942:dT
934:dT
930:dG
926:dA
924:*—
922:mC
920:*—
918:mU
916:*—
914:mC
912:*—
910:mC
908:*—
820:.
756:.
583:19
577:19
565:19
562:Na
559:67
131:US
1882:)
1878:/
1840:)
1836:(
1797:)
1793:(
1624:)
1591:)
1543:)
1479:)
1471:(
1406:)
1402:(
1398:/
1348:)
1344:(
1334:e
1327:t
1320:v
1303:.
1277:.
1194:.
1172::
1129:.
1103:.
1005:d
999:m
993:O
989:*
974:A
966:G
964:—
960:—
956:—
952:—
948:—
944:—
940:—
936:—
932:—
928:—
906:G
890:O
672:(
610:)
595:7
580:S
574:P
568:O
556:N
550:H
544:C
509:)
505:(
329:O
325:P
321:O
317:P
313:O
309:P
305:O
301:P
297:O
293:P
289:P
285:P
281:P
277:P
273:P
269:P
265:P
261:P
257:P
253:P
249:O
245:P
241:O
237:P
233:O
229:P
225:O
221:P
217:O
133::
62:/
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
